AMPH
Neutral signalScored 2026-09-27 Drivers: trend, fundamentals. Moteurs : tendance, fondamentaux.
Research, not advice.
À propos
Amphastar Pharmaceuticals, Inc.
- Nom
- Amphastar Pharmaceuticals, Inc.
- Secteur
- Healthcare
- Industrie
- Drug Manufacturers - Specialty & Generic
- Bourse
- NASDAQ
- Capitalisation
- $1.1B
- Employés
- 1,976
- PDG
- Yongfeng Zhang
- Site web
- https://www.amphastar.com
- Marché
- AMRXAYTUBHCCOLLCPHIETON
Amphastar Pharmaceuticals, Inc., established in 1996 and based in Rancho Cucamonga, California, functions as a biopharmaceutical enterprise. The company is engaged in the creation, production, commercialization, and distribution of both generic and proprietary pharmaceutical products, which include injectables, inhalants, and intranasal formulations. Its market presence extends across the United States, China, and France. Amphastar's operations are divided into two primary segments: Finished Pharmaceutical Products and Active Pharmaceutical Ingredients (API). The company's extensive product portfolio encompasses a variety of crucial medications. These feature Primatene Mist, an over-the-counter epinephrine inhaler for the temporary alleviation of mild asthma symptoms; Enoxaparin, a low molecular weight heparin utilized for the prevention and treatment of deep vein thrombosis; and Naloxone, an essential treatment for opioid overdose. Other significant offerings include emergency Glucagon injection kits; Cortrosyn, a diagnostic agent for adrenocortical insufficiency; and Amphadase, a bovine-sourced hyaluronidase injection that aids in the absorption and dispersion of other administered drugs. Amphastar additionally supplies Epinephrine injections for severe allergic reactions; various lidocaine products (such as a jelly for urological procedures and a topical solution for other applications); Phytonadione injection (Vitamin K1) for newborns; and specialized emergency syringe products for hospital use. Furthermore, the company provides Morphine injections for patient-controlled analgesia and Lorazepam injections for surgical and medical procedures. More advanced therapeutics consist of Neostigmine methylsulfate injection to manage myasthenia gravis and reverse muscle relaxant effects, and Isoproterenol hydrochloride injection for mild or transient episodes of heart block. Beyond its finished pharmaceutical goods, Amphastar also acts as a distributor for recombinant human insulin API and porcine insulin API. The company caters to a broad spectrum of healthcare providers, including hospitals, various care facilities, clinics, and physicians' offices.
Price (1 year)
Live chart from TradingView — independent market data, as price context around the filings, not the Quorum score. EMA 50/200 and Bollinger load by default. When the exchange is known it is sent as EXCHANGE:SYMBOL; otherwise TradingView resolves the ticker best-effort.
VENTE TOTALE: 4 139 titres (~103 475,00 $ US)
- Insiders
- PETERS WILLIAM J
- Total bought
-
—
Avg buy (VWAP, 90d window) —
- Total sold
-
$763,923
Avg sell (VWAP, 90d window) $22.82 vs last close $25.43 (+11.4%)
Total sold sums Form 4 code S in this window. Codes F, M, A and G are left out.
$287,361 of that total is under a Rule 10b5-1 plan. It is shown here and left out of the score.
- Last activity
- 2026-09-21
- Liquidity
- Thin $14,004,568/day · 20d vol
- Last synced
-
2026-10-02 21:10:04
Sign in to request a sync of this company's price history and timing levels.
Insider holdings as a share of total assets aren't available for this company.
Avg buy and avg sell are volume-weighted prices (sum of shares × price, divided by shares) for Form 4 rows in this 90-day window that report both figures. A comparison with last close is market context for that average, not advice.
Recent Form 4
Filings in the 90-day window for this company. Value is shares × price from the filing. Research, not advice.
| Date | Person | Side | Shares | Price | Value | Form 4 |
|---|---|---|---|---|---|---|
| 2026-09-21 | PETERS WILLIAM J | Sell · S · 10b5-1 | 4,139 | $25.00 | $103,475 | Form 4 |
| 2026-09-16 | Zhou Rong | Sell · S | 10,000 | $23.94 | $239,404 | Form 4 |
| 2026-09-02 | Zhou Rong | Sell · S | 3,187 | $23.63 | $75,306 | Form 4 |
| 2026-08-11 | PRINS RICHARD K | Sell · S | 7,973 | $20.30 | $161,852 | Form 4 |
| 2026-08-07 | PETERS WILLIAM J | Sell · S · 10b5-1 | 8,180 | $22.48 | $183,886 | Form 4 |
Sales marked 10b5-1 are scheduled in advance and don't count toward the Quorum score. Les ventes marquées 10b5-1 sont planifiées à l'avance et ne pèsent pas dans le score Quorum.
Congressional trades
STOCK Act disclosures (90-day window)
Amounts are STOCK Act brackets as disclosed. Quorum does not turn a bracket into an exact price or a midpoint.
No STOCK Act disclosures for this company in this window.
Signal
Neutral signalScored 2026-09-27 Drivers: trend, fundamentals. Moteurs : tendance, fondamentaux.
AMPH presents a conflicting profile: while liquidity remains solid (score 85), the deteriorating profitability trend, rising debt burden, and sharp decline in interest coverage ratios undermine the fundamental outlook…
The first sentence of the analysis written for AMPH on 2026-09-27 - a real excerpt, not a sample. The rest of it, the 0-100 score and the rating it produced are part of Plus. See plans.
Factor checklist — research, not advice
A check leans with a bullish reading. A cross leans against it. A dash is unavailable or mixed.
- Insider Pulls against a bullish reading. Selling cluster — sale value, no purchase value
- Congress Unavailable or mixed. No purchase disclosures in the stored window
- Narrative Pulls against a bullish reading. Stored narrative reading is in the bearish band
- Timing Supports a bullish reading. Interesting trend — weekly bias up
- Financial indicators Supports a bullish reading. Current ratio 4.02 · operating margin 20%
Suggested stop 24.92, nearest stored support minus 0.5 ATR(2.0% under the last close). Reward/risk to the next stored resistance is 1.30. Wait — that reward/risk is under 2. Research, not advice. Not an order.
Market snapshot
Financial ratios
| Metric | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|---|
| Gross Profit Margin | 49.5% | 51.1% | 54.5% | 49.9% | 45.6% | |
| Ebit Margin | 20.7% | 30.1% | 30.8% | 23.6% | 19.4% | |
| Ebitda Margin | 29.5% | 37.9% | 37.3% | 29.3% | 25.5% | |
| Operating Profit Margin | 19.5% | 28.1% | 30.6% | 21.5% | 16.0% | |
| Pretax Profit Margin | 17.2% | 25.8% | 26.3% | 23.0% | 19.2% | |
| Continuous Operations Profit Margin | 13.6% | 21.8% | 21.3% | 18.3% | 14.5% | |
| Net Profit Margin | 13.6% | 21.8% | 21.3% | 18.3% | 14.2% | |
| Bottom Line Profit Margin | 13.6% | 21.8% | 21.3% | 18.3% | 14.2% | |
| Current Ratio | 4.021 | 3.074 | 2.172 | 3.988 | 3.064 | |
| Quick Ratio | 2.903 | 2.189 | 1.703 | 2.896 | 2.170 | |
| Solvency Ratio | 0.192 | 0.256 | 0.205 | 0.561 | 0.392 | |
| Cash Ratio | 1.076 | 0.873 | 0.640 | 1.646 | 1.217 | |
| Price To Earnings Ratio | 12.752 | 11.286 | 21.702 | 14.904 | 17.915 | |
| Price To Earnings Growth Ratio | -0.353 | 0.731 | 0.421 | 0.334 | 0.004 | |
| Forward Price To Earnings Growth Ratio | -0.353 | 0.731 | 0.421 | 0.334 | 0.004 | |
| Price To Earnings Diluted Ratio | 13.192 | 12.134 | 23.788 | 16.103 | 18.632 | |
| Price To Earnings Diluted Growth Ratio | -0.392 | 0.686 | 0.481 | 0.411 | 0.004 | |
| Price To Book Ratio | 1.587 | 2.456 | 4.669 | 2.573 | 2.498 | |
| Price To Sales Ratio | 1.739 | 2.457 | 4.633 | 2.726 | 2.542 | |
| Price To Free Cash Flow Ratio | 10.325 | 10.434 | 20.540 | 20.882 | 15.775 | |
| Price To Operating Cash Flow Ratio | 8.018 | 8.427 | 16.268 | 15.254 | 11.355 | |
| Debt To Assets Ratio | 0.403 | 0.412 | 0.412 | 0.138 | 0.156 | |
| Debt To Equity Ratio | 0.832 | 0.888 | 0.975 | 0.194 | 0.235 | |
| Debt To Capital Ratio | 0.454 | 0.470 | 0.494 | 0.163 | 0.190 | |
| Long Term Debt To Capital Ratio | 0.436 | 0.451 | 0.480 | 0.121 | 0.143 | |
| Financial Leverage Ratio | 2.066 | 2.154 | 2.366 | 1.404 | 1.507 | |
| Working Capital Turnover Ratio | 1.718 | 2.344 | 2.353 | 2.005 | 2.293 | |
| Operating Cash Flow Ratio | 0.987 | 1.228 | 0.814 | 0.940 | 0.944 | |
| Operating Cash Flow Sales Ratio | 0.217 | 0.292 | 0.285 | 0.179 | 0.224 | |
| Free Cash Flow Operating Cash Flow Ratio | 0.777 | 0.808 | 0.792 | 0.731 | 0.720 | |
| Debt Service Coverage Ratio | 6.887 | 8.099 | 7.555 | 25.078 | 29.455 | |
| Interest Coverage Ratio | 5.510 | 6.770 | 7.253 | 58.232 | 78.968 | |
| Short Term Operating Cash Flow Coverage Ratio | 95.134 | 911.906 | 420.878 | 29.278 | 44.502 | |
| Operating Cash Flow Coverage Ratio | 0.238 | 0.328 | 0.294 | 0.869 | 0.936 | |
| Capital Expenditure Coverage Ratio | 4.476 | 5.199 | 4.808 | 3.711 | 3.569 | |
| Dividend Paid And Capex Coverage Ratio | 4.476 | 5.199 | 4.808 | 3.711 | 3.569 | |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Enterprise Value Multiple | 8.184 | 8.283 | 14.418 | 8.941 | 9.780 |
Sparkline shows each ratio oldest → newest (left → right).
How the latest year compares
For each ratio: its most recent value, the change versus one year earlier, and versus its 5-year average. ▲ higher ▼ lower
| Metric | Current | vs 1Y ago | vs 5Y avg |
|---|---|---|---|
| Gross Profit Margin | 49.5% | ▼-1.6% | ▼-0.6% |
| Ebit Margin | 20.7% | ▼-9.4% | ▼-4.2% |
| Ebitda Margin | 29.5% | ▼-8.4% | ▼-2.4% |
| Operating Profit Margin | 19.5% | ▼-8.6% | ▼-3.6% |
| Pretax Profit Margin | 17.2% | ▼-8.7% | ▼-5.1% |
| Continuous Operations Profit Margin | 13.6% | ▼-8.2% | ▼-4.3% |
| Net Profit Margin | 13.6% | ▼-8.2% | ▼-4.2% |
| Bottom Line Profit Margin | 13.6% | ▼-8.2% | ▼-4.2% |
| Current Ratio | 4.021 | ▲0.948 | ▲0.757 |
| Quick Ratio | 2.903 | ▲0.714 | ▲0.531 |
| Solvency Ratio | 0.192 | ▼-0.065 | ▼-0.130 |
| Cash Ratio | 1.076 | ▲0.203 | ▼-0.014 |
| Price To Earnings Ratio | 12.752 | ▲1.467 | ▼-2.959 |
| Price To Earnings Growth Ratio | -0.353 | ▼-1.084 | ▼-0.580 |
| Forward Price To Earnings Growth Ratio | -0.353 | ▼-1.084 | ▼-0.580 |
| Price To Earnings Diluted Ratio | 13.192 | ▲1.058 | ▼-3.578 |
| Price To Earnings Diluted Growth Ratio | -0.392 | ▼-1.078 | ▼-0.630 |
| Price To Book Ratio | 1.587 | ▼-0.869 | ▼-1.169 |
| Price To Sales Ratio | 1.739 | ▼-0.718 | ▼-1.080 |
| Price To Free Cash Flow Ratio | 10.325 | ▼-0.108 | ▼-5.266 |
| Price To Operating Cash Flow Ratio | 8.018 | ▼-0.408 | ▼-3.846 |
| Debt To Assets Ratio | 0.403 | ▼-0.010 | ▲0.098 |
| Debt To Equity Ratio | 0.832 | ▼-0.057 | ▲0.207 |
| Debt To Capital Ratio | 0.454 | ▼-0.016 | ▲0.100 |
| Long Term Debt To Capital Ratio | 0.435 | ▼-0.015 | ▲0.110 |
| Financial Leverage Ratio | 2.066 | ▼-0.089 | ▲0.166 |
| Working Capital Turnover Ratio | 1.718 | ▼-0.626 | ▼-0.425 |
| Operating Cash Flow Ratio | 0.987 | ▼-0.241 | ▲0.004 |
| Operating Cash Flow Sales Ratio | 0.217 | ▼-0.075 | ▼-0.022 |
| Free Cash Flow Operating Cash Flow Ratio | 0.777 | ▼-0.031 | ▲0.011 |
| Debt Service Coverage Ratio | 6.886 | ▼-1.212 | ▼-8.528 |
| Interest Coverage Ratio | 5.510 | ▼-1.260 | ▼-25.837 |
| Short Term Operating Cash Flow Coverage Ratio | 95.134 | ▼-816.772 | ▼-205.206 |
| Operating Cash Flow Coverage Ratio | 0.238 | ▼-0.090 | ▼-0.295 |
| Capital Expenditure Coverage Ratio | 4.476 | ▼-0.724 | ▲0.123 |
| Dividend Paid And Capex Coverage Ratio | 4.476 | ▼-0.724 | ▲0.123 |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 |
| Enterprise Value Multiple | 8.184 | ▼-0.099 | ▼-1.737 |
Key metrics
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Market cap | $1.25B | $1.80B | $2.99B | $1.36B | $1.11B | |
| Enterprise value | $1.74B | $2.30B | $3.46B | $1.31B | $1.09B | |
| EV / Sales | 2.41x | 3.14x | 5.38x | 2.62x | 2.49x | |
| EV / Op. cash flow | 11.13x | 10.77x | 18.88x | 14.65x | 11.13x | |
| EV / Free cash flow | 14.33x | 13.33x | 23.84x | 20.06x | 15.47x | |
| EV / EBITDA | 8.18x | 8.28x | 14.42x | 8.94x | 9.78x | |
| Net debt / EBITDA | 2.29x | 1.80x | 2.00x | -0.37x | -0.19x | |
| Current ratio | 4.02x | 3.07x | 2.17x | 3.99x | 3.06x | |
| Income quality | 1.59x | 1.34x | 1.33x | 0.98x | 1.55x | |
| Graham number | $28 | $33 | $29 | $21 | $17 | |
| Graham net-net | -$8 | -$9 | -$10 | $2 | $0 | |
| Tax burden | 79.3% | 84.3% | 81.2% | 79.6% | 74.0% | |
| Interest burden | 82.9% | 86.0% | 85.3% | 97.4% | 98.7% | |
| Working capital | $477.9M | $360.3M | $264.2M | $283.5M | $214.3M | |
| Invested capital | $1.40B | $1.30B | $1.19B | $585.3M | $524.7M | |
| Return on assets | 6.0% | 10.1% | 9.1% | 12.3% | 9.2% | |
| Operating ROA | 8.8% | 13.3% | 17.5% | 15.2% | 10.7% | |
| Return on tangible assets | 9.2% | 16.2% | 15.3% | 13.0% | 9.8% | |
| Return on equity | 12.4% | 21.8% | 21.5% | 17.3% | 13.9% | |
| Return on invested capital | 7.5% | 12.3% | 12.4% | 13.1% | 9.2% | |
| Return on capital employed | 9.5% | 14.6% | 15.3% | 16.6% | 12.3% | |
| Earnings yield | 7.8% | 8.9% | 4.6% | 6.7% | 5.6% | |
| Free cash flow yield | 9.7% | 9.6% | 4.9% | 4.8% | 6.3% | |
| Capex / Op. cash flow | 22.3% | 19.2% | 20.8% | 26.9% | 28.0% | |
| Capex / Depreciation | 55.2% | 71.7% | 91.4% | 83.6% | 102.6% | |
| Capex / Sales | 4.8% | 5.6% | 5.9% | 4.8% | 6.3% | |
| SG&A / Sales | 18.0% | 12.9% | 12.5% | 13.3% | 15.7% | |
| R&D / Sales | 11.9% | 10.1% | 11.4% | 15.0% | 13.9% | |
| Stock comp / Sales | 3.8% | 3.3% | 3.1% | 3.6% | 4.3% | |
| Intangibles / Total assets | 34.7% | 37.4% | 40.5% | 5.0% | 5.8% | |
| Days sales outstanding | 73d | 69d | 65d | 65d | 66d | |
| Days payables outstanding | 33d | 31d | 32d | 30d | 34d | |
| Operating cycle | 250d | 226d | 197d | 216d | 208d | |
| Cash conversion cycle | 218d | 194d | 165d | 186d | 174d |
Change by theme
Grouped by what each metric measures. Each figure is the change over the period shown — ▲ up ▼ down versus then.
Change over 1 year
Change over 5 years
Employee count
Peer market caps
Recent news
- 2026-09-20 Insider Selling: Amphastar Pharmaceuticals (NASDAQ:AMPH) EVP Sells $239,400.00 in Stock Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH - Get Free Report) EVP Rong Zhou sold 10,000 shares of Amphastar Pharmaceuticals stock in a transaction that occurred on Wednesday, September 16th. The stock was sold at an average price of $23.94, for a total value of $239,400.00. Following the completion of the transaction, the executive vice president owned 169,203
- 2026-09-01 Amphastar Pharmaceuticals to Present at the Wells Fargo 21st Annual Healthcare Conference RANCHO CUCAMONGA, Calif., Sept. 1, 2026 /PRNewswire/ -- Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) announced today that Bill Peters, CFO, and Tony Marrs, EVP of Regulatory Affairs and Clinical Operations, will be presenting at the Wells Fargo 21st Annual Healthcare Conference on Tuesday, September 8th, 2026, at 4:30 pm ET.
- 2026-08-27 3 Generic Drug Stocks to Watch Amid Improving Industry Trends The Medical - Generic Drugs industry gains from new launches, biosimilar momentum and portfolio shifts, despite pricing pressure and supply challenges.
- 2026-08-14 New Strong Sell Stocks for August 14th AMPH, CHT and HE have been added to the Zacks Rank #5 (Strong Sell) List on August 14, 2026.
- 2026-08-07 Amphastar Pharmaceuticals, Inc. (AMPH) Q2 2026 Earnings Call Transcript Amphastar Pharmaceuticals, Inc. (AMPH) Q2 2026 Earnings Call Transcript
- 2026-08-06 Compared to Estimates, Amphastar (AMPH) Q2 Earnings: A Look at Key Metrics Although the revenue and EPS for Amphastar (AMPH) give a sense of how its business performed in the quarter ended June 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
- 2026-08-06 Amphastar Pharmaceuticals Q2 Earnings Call Highlights Amphastar Pharmaceuticals NASDAQ: AMPH reported second-quarter 2026 revenue growth, supported by recently launched products including ipratropium bromide inhalation, while management said it is addressing an FDA warning letter at its IMS subsidiary and continuing investments in its pipeline and U.S. manufacturing operations.
- 2026-08-06 Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended June 30, 2026 Net revenues of $183.9 million for the three months ended June 30, 2026 GAAP net income of $30.3 million, or $0.67 per share, for the second quarter Adjusted non-GAAP net income of $40.8 million, or $0.91 per share, for the second quarter Company to hold a conference call today at 2:00 p.m. Pacific Time RANCHO CUCAMONGA, Calif.
- 2026-07-29 Amphastar Pharmaceuticals to Release Second Quarter Earnings and Hold Conference Call on August 6, 2026 RANCHO CUCAMONGA, Calif., July 29, 2026 /PRNewswire/ -- Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) announced today that the Company will release results for its second quarter of 2026 ended June 30, 2026, after the market closes on Thursday, August 6, 2026, and will hold a conference call to discuss its financial results at 2:00 p.m.
- 2026-07-22 Trump''s generic drug tariffs: What they could mean for medicine prices, manufacturers and supply Trump plans tariffs of up to 200% on imported generic drugs after a two-year grace period aimed at encouraging U.S. manufacturing. But thin profit margins make tariffs harder to absorb than for branded medicines and and key policy details remain unclear.